Thoracic Malignancy Steering Committee
The NCI Thoracic Malignancy Steering Committee (TMSC) was established in 2008.
The TMSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in clinical research of lung and other thoracic malignancies by addressing the design and prioritization of phase 3 trials and large phase 2 studies in chest malignancies. In addition to focusing on lung cancer, the TMSC addresses oncology trials in other thoracic sites, such as mesothelioma. Esophageal cancer trials are reviewed by the Gastrointestinal Steering Committee.
Clinical Trials Planning Meetings (CTPMs)
- Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer – February 2012
- Consensus Report of a Joint NCI/FDA Workshop Leading to the Inception of “Master Protocols” in Lung Cancer – Journal of Thoracic Oncology
The following are clinical trials that were approved at the concept stage by the Steering Committee:
|Trial ID||NCT ID||Trial Title|
|RTOG-0937||NCT01055197||Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)|
|RTOG-1106||NCT01507428||Randomized Phase II Trial of Individualized Adaptive Radiation Using During-Treatment FDG-PET/CT and Modern Radiation Technology to Dose Escalate in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|
|ECOG-E2511||NCT01642251||Phase II Randomized Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer|
|RTOG-1306/ALLIANCE_31101||NCT01822496||A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)|
|RTOG-1308||NCT01993810||Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC|
|SWOG-S1400||NCT02154490||Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer|
|SWOG-S1300||NCT02134912||A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients who have Progressed Systemically after Previous Clinical Benefit from Crizotinib Monotherapy|
|NCT02193282||Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)|
|ECOG-E4512||NCT02201992||A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein|
|RTOG-1021||NCT01336894||A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) Versus Stereotactic Body Radiation Therapy in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)|
|SWOG-S1403||NCT02438722||A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)|
|RTOG-1327||NCT02186847||Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer (NSCLC)|
CCCT Contact: Wolf Lindwasser, Ph.D.